Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$17.3 million.

  • Tg Therapeutics' Change in Accured Expenses fell 24808.47% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 7593.52%. This contributed to the annual value of $22.8 million for FY2024, which is 75375.7% up from last year.
  • Latest data reveals that Tg Therapeutics reported Change in Accured Expenses of -$17.3 million as of Q3 2025, which was down 24808.47% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Change in Accured Expenses ranged from a high of $65.6 million in Q1 2025 and a low of -$38.0 million during Q4 2024
  • Over the past 5 years, Tg Therapeutics' median Change in Accured Expenses value was $5.0 million (recorded in 2023), while the average stood at $2.7 million.
  • As far as peak fluctuations go, Tg Therapeutics' Change in Accured Expenses skyrocketed by 50173.76% in 2021, and later crashed by 756095.89% in 2022.
  • Over the past 5 years, Tg Therapeutics' Change in Accured Expenses (Quarter) stood at -$28.2 million in 2021, then surged by 158.17% to $16.4 million in 2022, then plummeted by 69.27% to $5.0 million in 2023, then crashed by 853.16% to -$38.0 million in 2024, then surged by 54.54% to -$17.3 million in 2025.
  • Its Change in Accured Expenses stands at -$17.3 million for Q3 2025, versus $5.6 million for Q2 2025 and $65.6 million for Q1 2025.